Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan i

Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial&#39

Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre

RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets αvβ6-integrin, a cellula

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl

Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-ma

RAD101 is the Company's novel Fluorine-18-labeled small-molecule imaging agent that targets fatt

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday&#39

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess

Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular

US stocks mixed, Dow Jones up 0.2%. Real estate shares up 1.3%. American Express falls 6%. Ohmyhome,

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's p

Radiopharm Theranostics Limited (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company&#34

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage ob

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sen

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranost

HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDA

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl

Key Findings from the AACR Abstract and PosterMeaningful tumor uptake of 177Lu-RAD202 was observed a

The U.S. multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic pe

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl

On track to share data from first two dose levels in 2H 2026Targeting KLK3 and leveraging the dual e

Radiopharm Theranostics says Phase 2b interim data showing 90% MRI concordance for RAD 101, with fin

Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage b

Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled w

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and R

Benzinga examined the prospects for many investors' favorite stocks over the last week — here&#3

B. Riley Securities analyst Yuan Zhi reiterates Radiopharm Theranostics (NASDAQ:RADX) with a Buy

Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 1

RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Ph

The interim analysis showed that 92% (11/12) of the patients treated with RAD 101 achieved concordan

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage b